Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations.
about
Inhibitory effects of Stemona tuberosa on lung inflammation in a subacute cigarette smoke-induced mouse modelLower 30-day readmission rates with roflumilast treatment among patients hospitalized for chronic obstructive pulmonary disease.Using PDE inhibitors to harness the benefits of calorie restriction: lessons from resveratrol.Metabolic benefits of inhibiting cAMP-PDEs with resveratrol.Roflumilast N-oxide prevents cytokine secretion induced by cigarette smoke combined with LPS through JAK/STAT and ERK1/2 inhibition in airway epithelial cells.
P2860
Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Roflumilast, a Novel Phosphodi ...... th a History of Exacerbations.
@en
Roflumilast, a Novel Phosphodi ...... th a History of Exacerbations.
@nl
type
label
Roflumilast, a Novel Phosphodi ...... th a History of Exacerbations.
@en
Roflumilast, a Novel Phosphodi ...... th a History of Exacerbations.
@nl
prefLabel
Roflumilast, a Novel Phosphodi ...... th a History of Exacerbations.
@en
Roflumilast, a Novel Phosphodi ...... th a History of Exacerbations.
@nl
P2860
P356
P1476
Roflumilast, a Novel Phosphodi ...... ith a History of Exacerbations
@en
P2093
Stephen K Field
P2860
P356
10.4137/CCRPM.S7049
P577
2011-10-18T00:00:00Z